Agitated Solutions, Inc. announced that the venture arm of W. L. Gore & Associates joined its Series B financing syndicate alongside Engage Venture Partners and individual investors.
Agitated Solutions, Inc. announced the first patient enrollment in its Phase 3 ENHANCE study, which assesses the safety and efficacy of ASI-02 in patients undergoing transthoracic echocardiography with agitated saline contrast.
Agitated Solutions, Incorporated (ASI) received European Union CE Mark approval for the Orbis Microbubble Generator, allowing it to be marketed in the EU.
Agitated Solutions, Inc. (ASI) is developing tools to enhance ultrasound imaging and diagnostic accuracy across multiple clinical applications. The FDA granted Fast Track designation to its inaugural product, ASI-02.
Bubble studies can vary in diagnostic value, and the lack of a unified solution can affect image quality and consistency and pose safety risks. Poor-quality images can lead to missed or inaccurate diagnoses or repeat studies.
Agitated Solutions, Inc. and its affiliated entities’ Privacy Policy describes the personal data collected through website and product use, how it is used, and users’ rights regarding that data.
